Evidence map›Paper›PMID 29786848›Full record

ArticleCancer2018

Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.

Kathleen A Cronin, Andrew J Lake, Susan Scott, Recinda L Sherman, Anne-Michelle Noone, Nadia Howlader, S Jane Henley, Robert N Anderson, Albert U Firth, Jiemin Ma and 2 more

2 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 555 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
555citing papers in PubMed, 6 pooled it
91.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04288739 unknown statusnot on this mapstarted 2020, after this paper: background citation

Relationship Between Immunophenotyping and X-inactive Specific Transcript (Xist) Gene in Acute Myeloid Leukemia

TypeobservationalSponsorAssiut UniversityRan2020 to 2022Enrolled65ConditionsAcute Myeloid LeukemiaArmsflow cytometric immunophenotyping, Xist gene by fluorescence insitu hybridization
NCT05643989 naunknown statusnot on this mapstarted 2019, after this paper: background citation

Randomized Non-inferiority Single-center Prospective Trial of Malignant Colonic Obstruction Therapy With Self-expandable Metal Stent (SEMS) Endoscopic Placement or Stoma Formation.

TypeinterventionalSponsorRussian Society of Colorectal SurgeonsRan2019 to 2023Enrolled56ConditionsNeoplasms,ColorectalArmsStoma formation, Endoscopic self-expandable metal stent placement
3 · Its place in the literature

Who cites it

555 citing papers in PubMed, 6 syntheses or guidelines pooled it, 1,525 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Injection laryngoplasty during transoral laser microsurgery for early glottic cancer: a randomized controlled trial.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2022
    Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Addressing algorithmic bias in lung cancer screening eligibility.Journal of the National Cancer Institute · 2026
    Article
  18. Article
  19. Review
  20. Article

495 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Kathleen A CroninDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
Andrew J LakeInformation Management Services, Inc., Rockville, Maryland.
Susan ScottDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0001-5881-8313
Recinda L ShermanNorth American Association of Central Cancer Registries, Springfield, Illinois.
Anne-Michelle NooneDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
Nadia HowladerDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.
S Jane HenleyDivision of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Robert N AndersonNational Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland.
Albert U FirthInformation Management Services, Inc., Rockville, Maryland.
Jiemin MaSurveillance and Health Services Research, American Cancer Society, Atlanta, Georgia.
Betsy A KohlerNorth American Association of Central Cancer Registries, Springfield, Illinois.
Ahmedin JemalSurveillance and Health Services Research, American Cancer Society, Atlanta, Georgia.ORCID 0000-0002-0000-4111
National Cancer Institute · USAmerican Cancer Society · USCenters for Disease Control and Prevention · USInformation Management Services · USNorth American Association of Central Cancer Registries · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates on cancer occurrence and trends in the United States.

methodsIncidence data were obtained from the CDC-funded and NCI-funded population-based cancer registry programs and compiled by NAACCR. Data on cancer deaths were obtained from the National Center for Health Statistics National Vital Statistics System. Trends in age-standardized incidence and death rates for all cancers combined and for the leading cancer types by sex, race, and ethnicity were estimated by joinpoint analysis and expressed as the annual percent change. Stage distribution and 5-year survival by stage at diagnosis were calculated for breast cancer, colon and rectum (colorectal) cancer, lung and bronchus cancer, and melanoma of the skin.

resultsOverall cancer incidence rates from 2008 to 2014 decreased by 2.2% per year among men but were stable among women. Overall cancer death rates from 1999 to 2015 decreased by 1.8% per year among men and by 1.4% per year among women. Among men, incidence rates during the most recent 5-year period (2010-2014) decreased for 7 of the 17 most common cancer types, and death rates (2011-2015) decreased for 11 of the 18 most common types. Among women, incidence rates declined for 7 of the 18 most common cancers, and death rates declined for 14 of the 20 most common cancers. Death rates decreased for cancer sites, including lung and bronchus (men and women), colorectal (men and women), female breast, and prostate. Death rates increased for cancers of the liver (men and women); pancreas (men and women); brain and other nervous system (men and women); oral cavity and pharynx (men only); soft tissue, including heart (men only); nonmelanoma skin (men only); and uterus. Incidence and death rates were higher among men than among women for all racial and ethnic groups. For all cancer sites combined, black men and white women had the highest incidence rates compared with other racial groups, and black men and black women had the highest death rates compared with other racial groups. Non-Hispanic men and women had higher incidence and mortality rates than those of Hispanic ethnicity. Five-year survival for cases diagnosed from 2007 through 2013 ranged from 100% (stage I) to 26.5% (stage IV) for female breast cancer, from 88.1% (stage I) to 12.6% (stage IV) for colorectal cancer, from 55.1% (stage I) to 4.2% (stage IV) for lung and bronchus cancer, and from 99.5% (stage I) to 16% (stage IV) for melanoma of the skin. Among children, overall cancer incidence rates increased by 0.8% per year from 2010 to 2014, and overall cancer death rates decreased by 1.5% per year from 2011 to 2015.

conclusionsFor all cancer sites combined, cancer incidence rates decreased among men but were stable among women. Overall, there continue to be significant declines in cancer death rates among both men and women. Differences in rates and trends by race and ethnic group remain. Progress in reducing cancer mortality has not occurred for all sites. Examining stage distribution and 5-year survival by stage highlights the potential benefits associated with early detection and treatment. Cancer 2018;124:2785-2800. © 2018 American Cancer Society.

Indexed as

CensusesAmerican Cancer SocietyCause of DeathFemaleHumansIncidenceMaleNational Cancer Institute (U.S.)NeoplasmsNeoplasm StagingPreventive Health ServicesSEER ProgramSex FactorsSurvival AnalysisUnited Statesand End Results (SEER)Annual Report to the NationcancerEpidemiologyincidencemortalityNational Program of Cancer Registries (NPCR)National Vital Statistics System (NVSS)North American Association of Central Cancer Registries (NAACCR)Surveillancesurvivaltrends

Identifiers

PMID29786848
PMCPMC6033186
OpenAlexW2803358834

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.